Binary or ternary mixture of solid dispersion: Meloxicam case

Ghaidaa Sulaiman Hameed¹, Masar Basim Mohsin Mohamed¹, Mohanad Naji Sahib²

¹ Department of Pharmaceutics, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq
² Faculty of Pharmacy, Al-Nisour University College, Al-Nisour Square, Baghdad, Iraq

Corresponding author: Ghaidaa Sulaiman Hameed (ghaidaahameed@uomustansiriyah.edu.iq)

Received 19 May 2022 ♦ Accepted 10 August 2022 ♦ Published 24 August 2022

Citation: Sulaiman Hameed G, Basim Mohsin Mohamed M, Naji Sahib M (2022) Binary or ternary mixture of solid dispersion: Meloxicam case. Pharmacia 69(3): 801–808. https://doi.org/10.3897/pharmacia.69.e86744

Abstract

The present work was carried out to assess the value of adding water insoluble polymer to meloxicam amorphous solid formulation (ASD). Meloxicam was mixed with polyvinylpyrrolidone (PVP) (1:1 ratio) as a binary mixture and with PVP and ethyl cellulose (1:1:1 ratio) as a ternary mixture. Solvent evaporation method was used to prepare ASD formulations. The differential scanning calorimetry, powder X-Ray diffraction, Cambridge Structural Database and in-vitro dissolution were performed to assess the formulas. The results showed that the addition of insoluble polymer could prevent the recrystallization process during ASD formation. However, the binary mixture showed higher drug release percentage than the ternary mixture. Therefore, a rational amount of insoluble polymer could be considered to control recrystallization and manipulate drug release from ASD formulations.

Keywords

Cambridge structure database, Meloxicam, Solid dispersion, Solvent evaporation

Introduction

Drug solubility is still a challenge for many formulators. Hence, many methods have been adapted to increase the solubility such as prodrugs, salt formation, micronization, and amorphous solid formation. The last method showed an increase in the solubility of many drugs such as indomethacin, ketoprofen and griseofulvin (Li et al. 2020; Rahman et al. 2020; Khiker et al. 2021). However, recrystallization issue usually arise during amorphous solid formation. (Kissi et al. 2018)

The presence of water soluble polymer is important to enhance drug water solubility (Aejaz et al. 2010; Sawafta et al. 2021). But, it also consider a source of recrystallization process due to polymer water adsorption (Baird and Taylor 2012; Sheokand et al. 2014). Literatures showed clearly this type of instability occurred with felodipine and ketoconazole with Polyvinylpyrrolidone (PVP) (Rumondor et al. 2009; Rumondor et al. 2011). Conversely, using a water insoluble polymer could enhance the stability of the amorphous solid dispersion (eg., ethyl cellulose with paracetamol amorphous solid dispersion) (Ghaly et al. 1993). The presence of water insoluble polymer is a double edged sword. In spite of improving the stability, they can retard the drug release from the mixture as in dipyriramol and cinnarizine with polyvinylpyrrolidone K30 and hydroxypropyl methylcellulose K100 (Baghel et al. 2018). Literatures showed an increased attention to use both water soluble and insoluble polymers together with the drug as a ternary mixture to increase both solubility and stability (Ohara et al. 2005; Alagdar et al. 2017; Liu et al. 2020). Nevertheless, PVP and ethyl cellulose polymers were not assessed yet.

Meloxicam (MEL) is a class II drug of the biopharmaceutical classification system (low aqueous solubility and...
high permeability) (Hirjäu et al. 2020). It has an analgesic effect due to its selectivity on inhibition COX-2 receptor (Fogle et al. 2021). It has a low molecular weight (351.4) and pKa values of 1.1 (hydroxyl group) and 4.2 (thiazole group) (Bednarczyk 2021; Zou et al. 2021). There were many methods used to enhance meloxicam water solubility such as micronization method, complexation with cyclodextrin, microemulsion and solid dispersion (Chiou et al. 2007; Shende et al. 2015; Ismail et al. 2021). As mentioned earlier, the binary mixture has many obstacles; hence, this work is designed to assess the effect of insoluble polymer (ethyl cellulose) addition to binary mixture of water soluble polymer (PVP) and meloxicam in amorphous solid dispersion preparation.

Materials and methods

Materials

Meloxicam was kindly donated form Al-Furat factory, Baghdad-Iraq, ethyl cellulose from Provizer pharma India, sodium lauryl sulphate (SLS) form Fluka chemical. Buchs, sodium dihydrogen orthophosphate dihydrate, di-sodium hydrogen orthophosphate dihydrate and methanol form Thomas baker, India. Polyvinylpyrrolidone K30 (PVP) was purchased from HiMedia Laboratories (India).

Preparation of physical mixture and solid dispersion formulations

Physical mixtures were prepared by mixing meloxicam with PVP (1:1) and with PVP:ethyl cellulose (1:1:1). The mixtures were triturated by hand using a mortar and pestle for 5 minutes at room temperature. Solid dispersion formulations were prepared by the solvent evaporation method. The required amount of drug and carrier in 1:1 ratios is weighed and blended in a porcelain dish. Then, the mixtures were dissolved in methanol. Afterward, the solvent was removed under reduced pressure for 20 min at 70 °C using a rotary vacuum evaporator. The obtained solid dispersions were pulverized in a mortar and sieved, then stored in a desiccator to be utilized for further characterizations.

Probability of H-bond formation

To assess the probability of bond formation between all materials, the H-bond in crystal structure was evaluated using Cambridge Structural Database (CSD) (Version 5.42, CCDC, Cambridge, UK). ConQuest was used to form the queries (version 3 CSDC, Cambridge, UK).

Differential scanning calorimetry (DSC)

All samples were examined by DSC 60 (Shimadzu, Japan). The samples were sealed in an aluminum pans (5–6 mg) and subject to heat (35 °C to 400 °C) at rate of 10 °C/min under an argon atmosphere.

Powder X-ray diffraction (PXRD)

The X-ray diffraction was measured using a powder X-ray diffractometer. The operating conditions were: current 30 mA, voltage 40 kV, and 1/min scanning speed with a range of 10–90° (2θ). The Degree of Crystallinity was calculated using Origin Lab software.

In-vitro release

Dissolution experiments for all formulations which equivalent to 15mg meloxicam (meloxicam powder, physical mixtures, binary and ternary mixtures) were performed using Cosmolab Type II dissolution apparatus, India, at 37 °C (100 rpm). The dissolution media was 900 mL water with SLS (0.2%) to ensure sink condition. At predetermined time intervals, 5 mL of samples were withdrawn and analyzed using UV-spectrophotometer (λmax = 363 nm). The same volume (maintained at 37 °C) was added to the dissolution media to maintain constant volume and sink condition. Model dependent and independent methods were used to compare meloxicam dissolution profiles. The model-dependent approaches included the zero order, the first order, the Hixson-Crowell, the Higuchi and the Weibull models. While the model independent approaches included Fit factors (difference factor f1, and the similarity factor fs), dissolution efficiency % (DE%), mean dissolution time (MDT). The results were compared using one-way analysis of variance (ANOVA) when applicable (SPSS Statistics 22).

Results and discussion

Prediction of H-bond formation

Stabilization of amorphous solid dispersions (ASD) is largely depend on specific drug-polymer interaction (Van Duong and Van den Mooter 2016). It is well known that H-bonding has a significant role in stabilizing ASD by preventing drug-drug or polymer-polymer intramolecular interaction (Janssens and Van den Mooter 2010; Van Duong and Van den Mooter 2016; Pugliese et al. 2021). The results revealed (Figs 1–3) good probabilities of H-bond formation between meloxicam and PVP, meloxicam and ethyl cellulose and PVP and ethylcellulose. Hence, the stability of ASD is highly anticipated. Consequently, these combinations can be selected for further assessment by DSC and XRPD to confirm the formation of the solid dispersion and its stability.

DSC

Fig. 4 shows the differential scanning calorimetry thermogram of meloxicam powder (as received) and meloxicam after solvent evaporation. It is clearly seen that the melting point of meloxicam as received is about 259 °C which similar to solvent evaporated meloxicam. This value was dissimilar from another report due to the
**Figure 1.** Probabilities of H-bond formation between meloxicam and polyvinylpyrrolidone (PVP) and the resonance probabilities.

**Figure 2.** Probabilities of H-bond formation between meloxicam and ethyl cellulose.
decomposition of meloxicam on melting (Ki and Choi 2007). The melting point of meloxicam showed an exothermic peak after melting around 264 °C and 266 °C respectively which reflect its decomposition (Pomázi et al. 2011). Moreover, there is no glass transition temperature (Tg) for meloxicam after solvent evaporation process. This indicated that meloxicam still in its crystalline form (Hancock and Zografi 1994; Megarry et al. 2014; Liu et al. 2018).

On the other hand, the physical mixture of meloxicam and PVP (Fig. 5) showed a melting peak around 84.9 °C in addition to the original melting point of meloxicam which is shifted downward to 231 °C with a sharp decline in the enthalpy. In addition, the thermogram showed no melting peak around 84.9 °C for a solvent evaporated mixture. This indicated water evaporation process of PVP polymer (El-Maradny et al. 2008; Noolkar et al. 2013). Meloxicam melting point peak showed significant reduction in the enthalpy (229.4 °C) with an exothermic peak around 258 °C. Furthermore, this mixture showed a Tg at 170 °C. The reduction in the enthalpy and the presence of Tg indicated that the mixture was in amorphous state (Li et al. 2016; Hameed 2017).

Moreover, Fig. 6 shows the thermogram of the physical mixture of meloxicam with PVP and ethylcellulose and after solvent evaporation process. It's clearly seen that the melting point peak of meloxicam was shifted to 252 °C with a distinct reduction in the enthalpy. Then again, the solvent evaporated mixture revealed Tg around 151.2 °C and a melting point peak at about 222 °C with sharp reduction in the enthalpy. The results suggested the formation of amorphous solid dispersion. These results were consistent with previous report (Setyawan et al. 2019). Moreover, these results suggested that the addition of water insoluble polymer (ethylcellulose) could prevent the recrystallization process (Hameed 2017).
**XRPD**

The DSC results revealed the amorphous formation of the binary and ternary mix. However, it did not confirm the stability of the formulations. The recrystallization process can be assessed quantitatively by calculating the Degree of Crystallinity (DC). Fig. 7 showed the XRPD of different formulas. The meloxicam powder showed sharp Bragg’s peaks which indicated a crystalline nature of meloxicam (Degree of Crystallinity (DC) = 36.41). After solvent evaporation process, this Bragg’s peaks unchanged except changing in the intensity (DC = 35.10) which might indicate a changing in the polymorphic type due to solvent effect (Bauer 2008).

The physical mixture of meloxicam and PVP showed a reduction in the intensity of Bragg’s peaks due to the dilution effect of the polymer (Ngo et al. 2018). However, the DC increased to 40.01. After solvent evaporation, there is an increase in the crystallinity of the mixture (DC = 42.46). The ternary mixture showed a further reduction in the Bragg’s peaks before and after solvent evaporation that might indicate a further reduction in the crystallinity of the mixture (DC = 35.68 (physical mixture), DC = 38.12 (after solvent evaporation)).

The overall results suggested that the ternary mixture had better stability than the binary mixture. Moreover, the results consistent with the previous report (Albadarin et al. 2017). In the present study, ethyl cellulose, a water insoluble polymer, had an important role in protection ASD from recrystallization process which results in a stable mixture. However, more work is needed to assess the effect of polymer concentration on the degree of crystallinity as shown in previous literature (Poralan et al. 2015).

**Dissolution study**

Fig. 8 shows the release of meloxicam powder (as received), meloxicam-PVP and meloxicam PVP-ethyl cellulose before and after solvent evaporation process. The figure revealed that meloxicam alone showed not more than 40% release although there was an increase in the release rate to about 60% for solvent evaporated meloxicam. This may be due to the changing in polymorphic state of the drug. Previous report showed that changing in the carbamazepine polymorphic state cause a change in the dissolution rate (Schrode et al. 2017).

The release rate of the physical mixture of meloxicam with PVP was increased from 40% to about 60% due to the presence of PVP which is water soluble polymer. After solvent evaporation, the release rate increased to about 90% which is consistent with the previous report (Fini et al. 2008). The ternary mix of meloxicam-PVP-ethyl cellulose release rate remains the same as meloxicam powder and this percent increased after solvent evaporation process to about 70%. Although the release rate is higher than meloxicam powder, it was lower than the release rate of the binary mixture due to the presence of ethyl cellulose.

The dissolution profiles corresponding to binary and ternary mixtures showed Hixon-Crowell model with the higher determination coefficients ($r^2$) and smallest AIC values (Table 1). This model describes the release according to the changes in the surface area and diameter of the particles. Moreover, the MDT showed insignificant difference between binary and ternary mixture ($P > 0.05$). However, the DE% showed higher values ($P < 0.05$) for binary mix-

**Table 1. Models fit for meloxicam formulations.**

| Model          | Statistics | Formulations |
|----------------|------------|--------------|
|                | $r^2$      | I  | II | III | IV | V  | VI |
| Zero order     | 0.816      | 0.968 | 0.995 | 0.962 | 0.985 | 0.982 |
|                | k          | 0.223 | 0.453 | 0.330 | 0.353 | 0.607 | 0.480 |
|                | AIC        | 35.33 | 31.84 | 14.92 | 29.57 | 30.71 | 28.39 |
|                | MSC        | 1.12  | 2.86  | 4.62  | 2.70  | 3.60  | 3.46  |
| First order    | 0.861      | 0.979 | 0.996 | 0.986 | 0.988 | 0.996 |
|                | k          | 0.004 | 0.008 | 0.004 | 0.007 | 0.017 | 0.010 |
|                | AIC        | 33.33 | 28.96 | 10.69 | 22.78 | 27.80 | 18.87 |
|                | MSC        | 1.41  | 3.28  | 4.94  | 3.72  | 3.89  | 4.82  |
| Hixon-Crowell  | r2         | 0.847 | 0.980 | 0.9943 | 0.999 | 0.994 | 0.996 |
|                | k          | 0.001 | 0.002 | 0.001 | 0.063 | 0.004 | 0.003 |
|                | AIC        | 34.04 | 28.44 | 13.06 | 8.99  | 23.03 | 17.40 |
|                | MSC        | 1.306 | 3.35  | 4.59  | 5.69  | 4.61  | 5.03  |
| Higuchi        | r2         | 0.888 | 0.965 | 0.993 | 0.992 | 0.994 | 0.995 |
|                | k          | 4.275 | 6.098 | 4.150 | 5.64  | 8.315 | 6.863 |
|                | AIC        | 32.00 | 32.50 | 15.32 | 18.63 | 23.82 | 19.53 |
|                | MSC        | 1.62  | 2.77  | 4.36  | 4.31  | 4.53  | 4.73  |
| Weibull        | r2         | 0.966 | 0.9818 | 0.996 | 0.977 | 0.995 | 0.996 |
|                | $\beta$    | 0.284 | 1.279 | 0.903 | 0.002 | 1.660 | 1.144 |
|                | AIC        | 25.51 | 29.89 | 13.54 | 25.95 | 24.26 | 19.57 |
|                | MSC        | 2.54  | 3.15  | 4.77  | 3.22  | 4.43  | 4.72  |
tute (Table 2). Previous literatures showed that the type of the polymer and its amount will affect the DE% (Fouad et al. 2021). Fit factors of the solvent evaporated formulations $f_1(22.27±1.03)$ and $f_2(42.04±0.93)$ showed significant difference between the binary and ternary mixture release. As a result, the addition of ethyl cellulose did not change mechanistic model or MDT. Nonetheless, the amount of the polymer had a crucial role in the overall dissolution efficiency.

I meloxicam powder; II solvent evaporated meloxicam powder; III physical mixture of meloxicam-PVP; IV solvent evaporated meloxicam-PVP mixture; V physical mixture of meloxicam-PVP- ethyl cellulose; VI solvent evaporated of meloxicam-PVP- ethyl cellulose mixture; red color bold font indicate model fit.

I meloxicam powder; II solvent evaporated meloxicam powder; III physical mixture of meloxicam-PVP; IV solvent evaporated meloxicam-PVP mixture; V physical mixture of meloxicam-PVP- ethyl cellulose; VI solvent evaporated of meloxicam-PVP- ethyl cellulose mixture; † significant differences between formulations ($P < 0.05$); ‡ insignificant differences between formulations ($P > 0.05$); * insignificant differences between two formulations ($P > 0.05$).

### Conclusion

Ternary mixture from hydrophilic and hydrophobic polymer can be used in a proper ratio to ensure both solubility and stability of amorphous solid dispersion formulation. The miscibility between the polymer mixtures is important to avoid phase separation in pharmaceutical pre-formulation which can be easily detected by CSDB through H-bond formation. From this study, the results acquired from DSC, XRPD analysis confirmed the conversion of meloxicam from crystalline to amorphous state. Moreover, the dissolution profile was greatly enhanced compared to meloxicam powder. Consequently, it was concluded that the addition of insoluble polymer could prevent the recrystallization process during ASD formation with an acceptable dissolution properties.

### Conflict of interests

The author reports no conflicts of interest in this work.

### References

Aejaz A, Jafar M, Dehghan M, Adil Shareef S (2010) Meloxicam-PVP-SLS ternary dispersion systems: in vitro and in vivo evaluation. International Journal of Pharmacy and Pharmaceutical Sciences 2(1): 182–190.

Albadarin AB, Potter CB, Davis MT, Iqbal J, Korde S, Pagire S, Paradkar A, Walker G (2017) Development of a binary carrier system consisting polyethylene glycol 4000-ethyl cellulose for ibuprofen solid dispersion. International Journal Of Pharmaceutical Investigation 7(3): 142–148. https://doi.org/10.4103/jphi.JPHI_54_17

Albadarin AB, Potter CB, Davis MT, Iqbal J, Korde S, Pagire S, Paradkar A, Walker G (2017) Development of stability-enhanced ternary solid dispersions via combinations of HPMCP and Soluplus processed by hot melt extrusion. International Journal of Pharmaceutics 532(1): 603–611. https://doi.org/10.1016/j.ijpharm.2017.09.035

Bagbél S, Cathcart H, O’Reilly NJ (2018) Investigation into the solid-state properties and dissolution profile of spray-dried ternary amorphous solid dispersions: a rational step toward the design and development of a multicomponent amorphous system. Molecular Pharmaceutics 15(9): 3796–3812. https://doi.org/10.1021/acs.molpharmaceut.8b00306

Baird JA, Taylor LS (2012) Evaluation of amorphous solid dispersion properties using thermal analysis techniques. Advanced Drug Delivery Reviews 64(5): 396–421. https://doi.org/10.1016/j.addr.2011.07.009

Bauer JF (2008) Polymorphism – A critical consideration in pharmaceutical development, manufacturing, and stability. Journal of Validation Technology 14(5): 15–24.

Bednarczyk D (2021) Passive influx and ion trapping are more relevant to the cellular accumulation of highly permeable low molecular weight acidic drugs than is Organic Anion Transporter 2 (OAT2). Drug Metabolism and Disposition 49(8): 648–657. https://doi.org/10.1124/dmd.121.000425

Chiou AH-J, Yeh M-K, Chen C-Y , Wang D-P (2007) Micronization of meloxicam using a supercritical fluids process. The Journal of Supercritical Fluids 42(1): 120–128. https://doi.org/10.1016/j.supflu.2006.12.024

El-Maradny H, Mortada S, Kamel O, Hikal A (2008) Characterization of ternary complexes of meloxicam-HIPPCD and PVP or L-arginine prepared by the spray-drying technique. Acta Pharmaceutica 58(4): 455–466. https://doi.org/10.2478/v10007-008-0029-9

Fini A, Cavallari C, Ospitali F (2008) Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles. European Journal of Pharmaceutics and Biopharmaceutics 70(1): 409–420. https://doi.org/10.1016/j.ejpb.2008.03.016

Fogle C, Davis J, Yechuri B, Cordle K, Marshall J, Blikslager A (2021) Ex vivo COX-1 and COX-2 inhibition in equine blood by phenylbuta-zone, flunixin meglumine, meloxicam and firocoxib: Informing clinical NSAID selection. Equine Veterinary Education 33(4): 198–207. https://doi.org/10.1111/eve.13280

### Table 2. Mean dissolution time and dissolution efficiency of different formulations.

| Variables | Formulations |
|-----------|--------------|
| Mean dissolution time (MDT)* | I II III IV V VI |
| Dissolution efficiency (DE) | 0.36±0.02† | 0.41±0.01‡ | 0.59±0.01‡ | 0.46±0.16† | 0.42±0.01*† | 0.29±0.02† |

The author reports no conflicts of interest in this work.
Ghaly E, Hernández J, Malavé A, Marti A (1993) Physicochemical characterization of acetaminophen-ethylcellulose solid dispersion. Puerto Rico Health Sciences Journal 12(4): 273–276.

Hameed G (2017) Investigation of cryomilling as a potential tool for the production of amorphous solid dispersions. PhD Thesis, University of Nottingham, United Kindom.

Hancock BC, Zograf G (1994) The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharmaceutical Research 11(4): 471–477. https://doi.org/10.1023/A:1018941810744

Hirjau M, Miron DS, Anuța V, Lupuliasa D, Ghica MV, Jinga V, Dinu-Pîrvu C-E (2020) Evaluation of experimental multi-particle polymer-coated drug delivery systems with meloxicam. Coatings 10(5): e490. https://doi.org/10.3390/coatings10050490

Ismael E, Elamini E, Ahmed E, Abdelrahman M (2021) Enhancement of Aqueous Solubility of Meloxicam using Solid Dispersions Based on Ziziphus spina-christi Gums. Drug Designing: Open Access 10: 188.

Janssens S, Van den Mooter G (2010) Review: physical chemistry of solid dispersion system with ethylcellulose and hydroxypropylmethylcellulose. International Journal of Pharmaceutics 362(1–2): 95–102. https://doi.org/10.1016/j.ijpharm.2005.06.019

Kissi EO, Grohganz H, Lobmann K, Ruggiero MT, Zeitler JA, Rades T (2011) Understanding the tendency of amorphous solid dispersions to undergo amorphous-amorphous phase separation in the presence of absorbed moisture. AAPS PharmSciTech 12(3): 197. https://doi.org/10.3390/pharmaceutics12030197

Kuhlak A, Khan S, Kharabe K, Singhavi D, Dahikar G (2021) Improvement in Aqueous Solubility of Citalipram by Amorphous Solid Dispersion, Its Formulation into Interpenetrating Polymer Network Microparticles and Optimization by Box-Behnken Design. FABAD 0(1): 00727

Kissi EO, Grohganz H, Lobmann K, Ruggiero MT, Zeitler JA, Rades T (2018) Glass-transition temperature of the β-relaxation as the major predictive parameter for recrystallization of neat amorphous drugs. The Journal of Physical Chemistry B 122(10): 2803–2808. https://doi.org/10.1021/acs.jpcb.7b10105

Li N, Cape JL, Mankani BR, Zemlyanov DY, Shepard KB, Morgen MM, Taylor LS (2020) Water-induced phase separation of spray-dried amorphous solid dispersions. Molecular Pharmaceutics 17(10): 4004–4017. https://doi.org/10.1021/acs.molpharmaceut.0c00798

Li S, Tian Y, Jones DS, Andrews GP (2016) Optimising drug solubilisation in amorphous polymer dispersions: rational selection of hot melt extrusion processing parameters. AAPS PharmSciTech 17(1): 200–213. https://doi.org/10.1007/s12249-015-0450-6

Liu T, Yao G, Zhang X, Zuo X, Wang L, Yin H, Möschwitzer JP (2018) Systematical Investigation of Different Drug Nanocrystal Technologies to Produce Fast Dissolving Meloxicam Tablets. AAPS PharmSciTech 19(2): 783–791. https://doi.org/10.1028/s12249-017-0889-8

Liu W, Wang S, Lu W, Cheng Z, Jiang N (2020) Sustained release ziprasidone microparticles prepared by spray drying with Soluplus and ethyl cellulose to eliminate food effect and enhance bioavailability. AAPS PharmSciTech 21(1): 1–8. https://doi.org/10.1208/s12249-019-1592-8

Megarry AJ, Booth J, Burley J (2014) Sucrose/Glucose molecular alloys by cryomilling. Journal of Pharmaceutical Sciences 103(7): 2098–2106. https://doi.org/10.1002/jps.24027

Ngo AN, Thomas D, Murowchick J, Aynon YJ, Iaiswal A, Youan B-RC (2018) Engineering fast dissolving sodium acetate mediated crystalline solid dispersion of docetaxel. International Journal of Pharmaceutics 545(1–2): 329–341. https://doi.org/10.1016/j.ijpharm.2018.04.045

Noolkar SB, Jadhav NR, Bhende SA, Killekar SG (2013) Solid-state characterization and dissolution properties of Meloxicam-Moringa Co-agulant-PVP ternary solid dispersions. AAPS PharmSciTech 14(2): 569–577. https://doi.org/10.1208/s12249-013-9941-5

Ohara T, Kitamura S, Kitagawa T, Terada K (2005) Dissolution mechanism of poorly water-soluble drug from extended release solid dispersion system with ethylcellulose and hydroxypropylmethylcellulose. International Journal of Pharmaceutics 302(1–2): 95–102. https://doi.org/10.1016/j.ijpharm.2005.06.019

Pomázi A, Ambrus R, Sipos P, Szabó-Révész P (2011) Analysis of co-spray-dried meloxicam-mannitol systems containing crystalline microcomposites. Journal of Pharmaceutical and Biomedical Analysis 56(2): 183–190. https://doi.org/10.1016/j.jpba.2011.05.008

Porolan G, Gambe J, Alcantara E, Vequizo R (2013) X-ray diffraction and infrared spectroscopy analyses on the crystallinity of engineered biological hydroxyapatite for medical application. In IOP conference series: materials science and engineering, Vol. 79, No. 1, p. 012028, 2015, IOP Publishing. https://doi.org/10.1088/1757-899X/79/1/012028

Pugliese A, Toresco M, McNamara D, Iuga D, Abraham A, Toby M, Hawarden LE, Blanc F (2021) Drug-Polymer Interactions in Acetaminophen/Hydroxypropylmethylcellulose Acetyl Succinate Amorphous Solid Dispersions Revealed by Multidimensional Multinuclear Solid-State NMR Spectroscopy. Molecular Pharmaceutics 18(9): 3519–3531. https://doi.org/10.1021/acs.molpharmaceut.1c00427

Rahman M, Ahmad S, Tarabokija J, Parker N, Bilgili E (2020) Spray-dried amorphous solid dispersions of griseofulvin in HPC/soluplus/SDS: Elucidating the multifaceted impact of SDS as a minor component. Pharmaceutics 12(3): 197. https://doi.org/10.3390/pharmaceutics12030197

Rumondor AC, Ivanisevic I, Bates S, Alonzo DE, Taylor LS (2009) Evaluation of drug-polymer miscibility in amorphous solid dispersion systems. Pharmaceutical Research 26(11): 2523–2534. https://doi.org/10.1007/s11095-009-9970-7

Rumondor AC, Wikström H, Van Eerdenbrugh B, Taylor LS (2011) Understanding the tendency of amorphous solid dispersions to undergo amorphous-amorphous phase separation in the presence of absorbed moisture. AAPS PharmSciTech 12(4): 1209–1219. https://doi.org/10.1208/s12249-011-9686-y

Sawaf A, Alhadin S, Awwad IAA, Migdadi E, Aljaberi A (2021) Impact of the manufacturing technique on the dissolution-enhancement functionality of PEG4000 in Calostazol tablets. Pharmac 68(1): 243–250. https://doi.org/10.1389/pharmacia.68.e62465

Schröde B, Bodak B, Riegler H, Zimmer A, Christian P, Werzer O (2017) Solvent Vapor Annealing of Amorphous Carbamazepine...
Films for Fast Polymorph Screening and Dissolution Alteration. ACS omega 2(9): 5582–5590. https://doi.org/10.1021/acsome-ga.7b00783

Setyawan D, Dewi MY, Isadiartuti D (2019) Ternary solid dispersion to improve solubility and dissolution of meloxicam. Journal of Basic and Clinical Physiology and Pharmacology 30(6): e0244. https://doi.org/10.1515/jbcpp-2019-0244

Shende PK, Gaud R, Bakal R, Patil D (2015) Effect of inclusion complexation of meloxicam with β-cyclodextrin- and β-cyclodextrin-based nanosponges on solubility, in vitro release and stability studies. Colloids and Surfaces B: Biointerfaces 136: 105–110. https://doi.org/10.1016/j.colsurfb.2015.09.002

Sheokand S, Modi SR, Bansal AK (2014) Dynamic vapor sorption as a tool for characterization and quantification of amorphous content in predominantly crystalline materials. Journal of Pharmaceutical Sciences 103(11): 3364–3376. https://doi.org/10.1002/jps.24160

Van Duong T, Van den Mooter G (2016) The role of the carrier in the formulation of pharmaceutical solid dispersions. Part II: amorphous carriers. Expert Opinion on Drug Delivery 13(12): 1681–1694. https://doi.org/10.1080/17425247.2016.1198769

Zou L, Matsson P, Stecula A, Ngo HX, Zur AA, Giacomini KM (2021) Drug metabolites potently inhibit renal organic anion transporters, OAT1 and OAT3. Journal of Pharmaceutical Sciences 110(1): 347–353. https://doi.org/10.1016/j.xphs.2020.09.004